VERVE-101, a CRISPR base-editing therapy designed to permanently inactivate hepatic PCSK9 and reduce LDL-cholesterol.

Authors :: Hooper AJ
Tang XL
Burnett JR
Source :: Expert opinion on investigational drugs [Expert Opin Investig Drugs] 2024 Aug; Vol. 33 (8), pp. 753-756. Date of Electronic Publication: 2024 Jun 21.
Publication Year :: 2024

Subjects :: Humans
Animals
Genetic Therapy methods
CRISPR-Cas Systems
Liver
Proprotein Convertase 9 genetics
Cholesterol, LDL blood
Gene Editing methods

Full Text Access

Tools